Intraperitoneal administration of a neutrophil-neutralizing antibody (anti-Ly6G) in a NASH-murine model (10-week HFD-fed C57BL/6 mice) reduced neutrophil liver infiltration, ameliorated metabolic features (reduction of fasting glycemia, hepatic TG content and transaminase activity), decreased hepatic inflammation (abrogation of macrophage infiltration and expression of proinflammatory cytokines such as TNFα, IL-6 and MCP-1) and profibrotic environment (reduction of profibrotic cytokine hepatic expression, such as TGF-β and α-smooth muscle actin (α-SMA)) [58]. This evidence concerns the gene CCL2 and metabolic dysfunction-associated steatohepatitis.